Stephen J. Fey has a background in biomedical science having worked in research universities and companies for the past 40 years.

He obtained his PhD at Kings College, London University and had the fun of teaching practical courses with Nobel laureate Maurice Wilkins. He became a pioneer in 2D gel electrophoresis using 2DGE to study cervical cancer, diabetes and cardiovascular problems. Steve has 125 publications in peer-reviewed scientific journals and has filed 38 patents.

He was the co-founder of the Centre for Proteome Analysis in 1997 (a new institute at the University of Southern Denmark & the world’s first purpose built proteomics institute) and became CEO when the institute was spun out of the SDU to become DrugMode ApS in 2006. In 2011 he became TCEL group leader at SDU, developing 3D cell and tissue culture systems to mimic in vivo physiology and toxicology. He was co-founder of CelVivo in 2014, a spin out company, commercialising the revolutionary ClinoStar® and ClinoReactor™ for 3D cell culture.